Choose your country to see the products for your location
SALSA® MLPA® Probemix P051 Parkinson mix 1 detects duplications and triplications in the SNCA gene, deletions and duplications in the PARK2 gene, and the presence of one point mutation, G2019S in the LRRK2 gene, and can be used together with SALSA® MLPA® Probemix P052 Parkinson mix 2, which also detects deletions and duplications in the PARK2 gene, and the presence of the G2019S LRRK2 point mutation.
Contents:
Tissue: genomic DNA isolated from human peripheral whole blood.
Application: early-onset (PARK2 deletions/duplication, SNCA triplications, LRRK2 G2019S mutation) and late-onset (SNCA duplications, LRRK2 G2019S mutations) Parkinson's disease.
IVDR certified and registered for in vitro diagnostic (IVD) use in selected territories.
This product has recently been CE-marked for in vitro diagnostic (IVD) use under the In Vitro Diagnostic Regulation (IVDR; EU 2017/746), which replaces the former CE-marking under the IVD Directive (IVDD; Directive 98/79/EC). This update was accompanied by a change in the intended purpose and a change in format of the product description. Some information can now be found in a different location (more information).
The SALSA MLPA Probemixes P051 Parkinson mix 1 and P052 Parkinson mix 2 are in vitro diagnostic (IVD) or research use only (RUO) semi-quantitative manual assays for the detection of duplications and triplications in the SNCA gene (P051), deletions and duplications in the PARK2 gene, and the presence of one point mutation, G2019S in the LRRK2 gene (P051 and P052), in genomic DNA isolated from human peripheral whole blood specimens. P051 Parkinson mix 1 and P052 Parkinson mix 2 are intended to confirm a potential cause for early-onset (PARK2 deletions/duplication, SNCA triplications, LRRK2 G2019S mutation) and late-onset (SNCA duplications, LRRK2 G2019S mutations) Parkinson's disease and for molecular genetic testing of at-risk family members.
For the full intended purpose, see the product description.
Parkinson's disease is the second most common neurodegenerative disorder and is characterized by the degeneration of dopaminergic neurons of the midbrain. Resting tremor, bradykinesia, rigidity, and postural instability are the main clinical manifestations of the disease, and further motor complications can arise as the disease progresses. Further, in 30-40% of cases, dementia and/or psychosis occur. The most common age of onset for PD is around 60 years (the disease is characterised as Late-Onset or LOPD from 50 years of age), but this can vary. Early-onset PD (EOPD) is a form of the disease in which the first symptoms appear between the ages of 20-50 years. Additionally, juvenile PD (PDJ) is described when the first symptoms appear at 20 years of age or even earlier. The majority of Parkinson's disease cases are sporadic and a family history is reported in approximately 15% of patients. There are more than 10 million people worldwide with PD. The age-standardized prevalence rate for PD in the United Kingdom is around 140 per 100,000 population. The incidence increases with age and it is estimated that 4% of PD patients are diagnosed before the age of 50.
Parkinson's disease is assumed to be multifactorial in most cases, caused by a combination of genetic and environmental risk factors. The most important "environmental" risk factor is aging.
Mutations in multiple genes are associated with autosomal dominant (SNCA, LRRK2, GCH1, UCHL1) or autosomal recessive (PARK2 (also known as PRKN), PINK1, PARK7, ATP13A2) Parkinson's disease. Mutations in these genes range from point mutations to larger exonic rearrangements including deletions and duplications. The presence of multiple copies of SNCA is known to be associated with Parkinson's disease and the severity of symptoms increases with the number of copies of the gene (Keyser et al. 2010, Matsumoto et al. 2010). Duplications lead to LOPD, while triplications lead to a more severe form of EOPD with dementia. The LRRK2 G2019S mutation (p.Gly2019Ser, c.6055G>A) is the most common Parkinson-associated mutation known today and has been reported in 41% of sporadic and 37% of familial Parkinson patients from the North African Arab population and in 18.3% of Ashkenazi Jewish Parkinson patients (Lesage et al. 2006, Ozelius et al. 2006), while the mutation has been found in only 0.58% Parkinson patients of European and Asian origin (Ross et al. 2011).
Mutations in PARK2 and PINK1 are the most common causes of EOPD, however the frequencies vary widely across studies. It has been reported that up to 50% of familial and 18% of sporadic EOPD cases had pathogenic PARK2 mutations, whereas more recent studies have reported a pathogenic mutation frequency as low as 1.6%. Frequency estimates for PINK1 mutations tend to fall within a similarly broad range as for PARK2, whereas PARK7 mutations are generally very rare, being estimated in a UK-based study in 0.4% (Kilarski et al. 2012). Parkinson-related mutations in ATP13A2, GCH1 and UCHL1 are very rare.
More information is available on https://www.ncbi.nlm.nih.gov/books/NBK1223/ and https://www.ncbi.nlm.nih.gov/books/NBK1478/.
SALSA MLPA Probemix P051 Parkinson mix 1 is CE-marked under the IVDR for in vitro diagnostic (IVD) use in Europe. This assay has also been registered for IVD use in Israel.
This assay is for research use only (RUO) in all other territories.
SALSA Binning DNA SD067 is an artificial DNA sample with a signal for all probes in the P051 Parkinson mix 1 probemix. Inclusion of a reaction with SD067 in initial experiments and in experiments following a change in electrophoresis conditions is recommended to aid in the creation of a bin set that links peaks to the probes that produce them. Binning DNA cannot be used as a reference sample in the MLPA data analysis, and cannot be used to quantify the signals of mutation-specific probes.
A vial of SALSA Binning DNA SD067 is included with every order of the P051 Parkinson mix 1 probemix, but it is possible to order additional vials separately.
For more information, see the product description.
Translations of the product description in selected European languages are available upon request. Please contact us or one of our local sales partners. Translations of the MLPA General Protocol in selected languages are available here.
The Summary of Safety and Performance (SSP) is also available upon request.
A general SALSA MLPA Reagent Kit is required for MLPA experiments (to be ordered separately).
A vial is included with every order of this probemix, but additional vials can also be purchased separately.
The prices above are list prices for direct orders from MRC Holland. Contact us for a quote that takes discounts and additional costs (such as shipping costs) into account. Different prices apply for orders through one of our sales partners; contact your local supplier for a quote.
Inclusion of a positive sample is usually not required, but can be useful for the analysis of your experiments. MRC Holland has very limited access to positive samples and cannot supply such samples. We recommend using positive samples from your own collection. Alternatively, you can use positive samples from an online biorepository, such as the Coriell Institute.
The commercially available positive samples below have been tested with the current (D2) version of this product and have been shown to produce useful results.